Month: October 2018

Biotech Research and Development Collaborations

Small and early-stage biotech companies often have severely limited resources for performing critical proof of concept (PoC) experiments. Sometimes, very early companies don’t even have in-house scientific capabilities. In these cases, outsourcing research is essential to producing value. Contract research organizations (CROs) and contract manufacturing organizations (CMOs) can fill in…

From the clinic to FDA approval

Last week, I wrote about the preclinical side of drug discovery: from target discovery through screening and optimization, IND-enabling studies, and finally the components of the IND itself. So say the IND is approved, then what? Here, I will discuss the general path through clinical trials. Note along the way…

From discovery to the clinic

It is well known, especially for readers of this blog, that once biotech companies discover a new potential therapeutic, they take it through clinical trials in order to market the drug to actual patients. But how do biotechs come up with these clinical candidates, and how are potential drugs de-risked…

How do biotech companies raise capital?

What are some ways in which biotechs can raise money? Research and development is expensive, especially in the biotech realm. Cells, antibodies, animal models, infrastructure, etc. can lead to individual experiments costing thousands of dollars. So how do pre-revenue companies raise money to perform their experiments? How can they de-risk…

Smid-Cap Biotech Stock Catalysts

Biotwitter and the media are constantly sharing and discussing breaking biotech news: clinical trial outcomes, FDA decisions, and on and on. In turn, biotech stock valuations can change substantially very quickly. This is most pronounced in smaller, riskier companies with a single or small number of assets. So, what are…